From mechanisms to long-term benefits

Transplantation

Volumn 79, Issue 3 SUPPL., 2005, Pages

  Mamelok, Richard ^a  

^a Mamelok Consulting   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD134 ANTIGEN; CYCLOSPORIN; INOSINATE DEHYDROGENASE; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR ALPHA; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NITRIC OXIDE SYNTHASE; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; AREA UNDER THE CURVE; CELL ADHESION; CELL PROLIFERATION; CONFERENCE PAPER; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG ABSORPTION; DRUG MECHANISM; DRUG METABOLISM; DRUG PROTEIN BINDING; ENTEROHEPATIC CIRCULATION; ENZYME INHIBITION; FIBROBLAST; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; SMOOTH MUSCLE FIBER;

ANIMALS; ENZYME INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; MYCOPHENOLIC ACID; TRANSPLANTATION IMMUNOLOGY;

EID: 14344265460     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000153301.27572.B2     Document Type: Conference Paper

References (13)

1. Bullingham RE, Nicholls AJ, and Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinetics 1998; 34: 429.
2. Kobashigawa J, Miller L, Renlund D, et al. A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators. Transplantation 1998; 66: 507.
3. Ojo AO, Meier-Kriesche HU, Hanson JA, et al. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 2000; 69: 2405.
4. Lake JR, Chu AH, Bettina JS, et al. Efficacy of triple therapy with mycophenolate mofetil (MMF), tacrolimus (TACRO), and corticosteroids (CS) compared to TACRO and CS immunosuppression in liver transplantation: an analysis of the US Liver Transplant experience. Am J Transplantation 2004; 4 (Suppl): 266.
5. Eugui EM, Almquist SJ, Muller CD, Allison AC. Lymphocyte-selective cytostatic and immunosuppressive effects of mycophenolic acid in vitro: role of deoxyguanosine nucleotide depletion. Scand J Immunol 1991; 33: 161.
6. Allison AC and Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000; 47: 85.
7. Braun KP, Glander P, Hambach P, et al. Pharmacokinetics and pharmacodynamics of mycophenolate mofetil under oral and intravenous therapy. Transplantation Proc 2002; 34: 1745.
8. Budde K, Braun KP, Glander P, et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplantation Proc 2002; 34: 1748.
9. Gummert JF, Barten MJ, van Gelder T, et al. Pharmacodynamics of mycophenolic acid in heart allograft recipients: correlation of lymphocyte proliferation and activation with pharmacokinetics and graft histology. Transplantation 2000; 70: 1038.
10. Raisanen-Sokolowski A, Vuoristo P, Myllarniemi M, et al. Mycophenolate mofetil (MMF, RS-61443) inhibits inflammation and smooth muscle cell proliferation in rat aortic allografts. Transplant Immunology 1995; 3: 342.
11. Azuma H, Binder J, Heemann U, et al. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 1995; 59: 460.
12. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc 1999; 31: 1250.
13. Jurcevic S, Ainsworth ME, Pomerance A, et al. Antivimentin antibodies are an independent predictor of transplant-associated coronary artery disease after cardiac transplantation. Transplantation 2001; 71: 886.